Adipic acid dihydrazide

ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028

Retrieved on: 
Monday, July 18, 2022

FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, according to a recent study by Bosson Research, the global Retinal Surgical Instruments market, valued at USD 1.59 billion in 2021, is expected to reach USD2.46 billion by the end of 2028, growing at a CAGR of 6.08% between 2022 and 2028.  This growth is expected to benefit ABVC’s development of its medical device, Vitargus, a gel-like substance that aims to help the eye maintain a round shape and keep the retina in place during and after retina re-attachment surgery.

Key Points: 
  • Growing instances of retinal disorders in the geriatric population, eye injuries and rising prevalence of diabetic retinopathy are the key driving factors in the retinal surgery devices market.
  • ABVCs Vitargus is a medical device intended to solve an important issue faced by surgeons following retinal re-attachment, namely patient comfort.
  • This allows for a variety of repairs, including the removal of scar tissue, laser repair of retinal detachments and treatment of macular holes.
  • Global Retinal Surgery Devices Market Research Report 2022 (Status and Outlook).